To include your compound in the COVID-19 Resource Center, submit it here.

Keytruda pembrolizumab: Additional Phase Ib data

Data from 26 heavily pretreated patients with salivary gland carcinoma in the open-label, international Phase Ib KEYNOTE-028 trial showed that 10 mg/kg IV Keytruda every 2 weeks for up

Read the full 290 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE